Potassium Channel News and Research RSS Feed - Potassium Channel News and Research

Study reports results of genetic testing for 22 genetic causes of neonatal diabetes

Study reports results of genetic testing for 22 genetic causes of neonatal diabetes

Over a 10 year period, the time that babies receive genetic testing after being diagnosed with diabetes has fallen from over four years to under two months. Pinpointing the exact genetic causes of sometimes rare forms of diabetes is revolutionising healthcare for these patients. [More]
Neuroscientist discovers how animal's biological clock wakes up, goes to sleep

Neuroscientist discovers how animal's biological clock wakes up, goes to sleep

Fifteen years ago, an odd mutant fruit fly caught the attention and curiosity of Dr. Ravi Allada, a circadian rhythms expert at Northwestern University, leading the neuroscientist to recently discover how an animal's biological clock wakes it up in the morning and puts it to sleep at night. [More]
Ion channel blockers prove useful in cancer therapy

Ion channel blockers prove useful in cancer therapy

Drugs called ion channel blockers, which are commonly used to treat cardiac, neurological, and psychiatric disorders, might prove useful in cancer therapy, according to research findings in fruit flies and mice by UC San Francisco scientists that led to unconventional treatment of a case of metastatic brain cancer. [More]
Brain protein plays key role in controlling binge drinking

Brain protein plays key role in controlling binge drinking

Scientists at The Scripps Research Institute have discovered that a brain protein has a key role in controlling binge drinking in animal models. They found that deleting the gene for this protein in mice ramped up alcohol consumption and prevented the brain from signaling the rewarding properties of alcohol. [More]
European scientists identify gene linked with certain types of early-onset epilepsy

European scientists identify gene linked with certain types of early-onset epilepsy

Certain types of early-onset epilepsy are caused by previously unknown mutations of a potassium channel gene, KCNA2. The mutations disrupt the electrical balance in the brain in two ways. In some patients, the flow of potassium is greatly reduced; while in others, it is raised enormously. Both states can lead to hard-to-treat epileptic seizures. Mental and motor development can come to a stop, or even to regress. [More]
USF researchers awarded grant to test new drug for age-related hearing loss

USF researchers awarded grant to test new drug for age-related hearing loss

A successful treatment for age-related hearing loss (ARHL) is a step closer to reality, thanks to a group of researchers from the University of South Florida. The research team comprised of faculty and students has been awarded $400,000 by Autifony Therapeutics, Ltd, a company based in the United Kingdom, to test a new drug the company developed for ARHL. [More]
Retigabine drug could reduce debilitating impact of strokes

Retigabine drug could reduce debilitating impact of strokes

New research suggests that an already-approved drug could dramatically reduce the debilitating impact of strokes, which affect nearly a million Americans every year. [More]
Damon Runyon Cancer Research Foundation names 15 new Damon Runyon Fellows

Damon Runyon Cancer Research Foundation names 15 new Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 15 new Damon Runyon Fellows at its fall Fellowship Award Committee review. The recipients of this prestigious, four-year award are outstanding postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators across the country. [More]
Study identifies new gene for progressive form of epilepsy

Study identifies new gene for progressive form of epilepsy

A study led by researchers at University of Helsinki, Finland and Universities of Melbourne and South Australia has identified a new gene for a progressive form of epilepsy. The findings of this international collaborative effort have been published today, 17 November 2014, in Nature Genetics. [More]
Researchers discover new genetic cause of rare, complex form of epilepsy

Researchers discover new genetic cause of rare, complex form of epilepsy

A research team led by scientists at the Scripps Translational Science Institute has used whole genome sequencing to identify a new genetic cause of a severe, rare and complex form of epilepsy that becomes evident in early childhood and can lead to early death. [More]
Light-activated diabetes drug: an interview with Dr David Hodson

Light-activated diabetes drug: an interview with Dr David Hodson

We've known about chemicals that can be light-activated for about five to ten years now. They’ve mainly all been applied to neurons and, more specifically, the retina. Nobody has ever really looked at any tissues outside of the nervous system. [More]
Cypher researchers identify new genetic cause of severe epileptic encephalopathy

Cypher researchers identify new genetic cause of severe epileptic encephalopathy

Cypher Genomics, Inc., the genome informatics company, announced today the identification of de novo KCNB1 missense mutations as a novel genetic cause of severe epileptic encephalopathy. Cypher’s co-founder and Chief Scientific Officer Ali Torkamani, Ph.D. reviewed the data today at a platform presentation at the ASHG 2014 meeting being held October 18 to 22 in San Diego. [More]
Tannic acid may help ease impact of bacterial lung infections in CF patients

Tannic acid may help ease impact of bacterial lung infections in CF patients

By screening over 2,000 approved drugs and natural products, scientists have shown that tannic acid may help ease the impact of bacterial lung infections in cystic fibrosis patients. [More]
Empirical sulphonylurea therapy an option for neonatal diabetes

Empirical sulphonylurea therapy an option for neonatal diabetes

A report of empirical sulphonylurea therapy in neonatal diabetes prior to genetic diagnosis highlights contrasting approaches to the problem. [More]
Mice who have partial deficiency of gene SENP2 are more likely to develop seizures, sudden death

Mice who have partial deficiency of gene SENP2 are more likely to develop seizures, sudden death

A gene crucial for brain and heart development may also be associated with sudden unexplained death in epilepsy (SUDEP), the most common cause of early mortality in epilepsy patients. [More]
Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts believe a molecule in parasitic worms could help explain why worm infections can effectively treat a range of autoimmune diseases, including multiple sclerosis, psoriasis, rheumatoid arthritis and lupus. [More]
Dosing commences in Essentialis’ DCCR clinical study in obese Prader-Willi syndrome patients

Dosing commences in Essentialis’ DCCR clinical study in obese Prader-Willi syndrome patients

Essentialis announced today the dosing of the first patient in clinical study PC025, which is designed to evaluate the safety and efficacy of diazoxide choline controlled release tablets (DCCR) in obese Prader-Willi syndrome patients. [More]
Autifony Therapeutics awarded £2.2 million to progress first-in-class drug for tinnitus into Phase IIa study

Autifony Therapeutics awarded £2.2 million to progress first-in-class drug for tinnitus into Phase IIa study

Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that it has been awarded funding of £2.2 million towards a Phase IIa clinical trial in tinnitus patients with its lead compound AUT00063, by the UK’s innovation agency, the Technology Strategy Board. [More]

Researchers discover that anti-seizure drug reduces alcohol consumption

Boston-Researchers from Boston University School of Medicine (BUSM) have discovered that the anti-seizure drug ezogabine, reduced alcohol consumption in an experimental model. The findings, reported in the American Journal of Drug and Alcohol Abuse, may lead to more effective treatments for alcoholism. [More]
Servier Joins Xention To Develop AF Drug In Up To $163.2M Deal

Servier Joins Xention To Develop AF Drug In Up To $163.2M Deal

... [More]
Advertisement
Advertisement